Meclizine is the antihistamine in motion sickness tablets and vertigo treatments, sold both over the counter and by prescription depending on strength and brand. Employees who take it before a flight, a boat trip, or for inner ear symptoms sometimes ask whether it can turn a routine workplace drug screen into a disputed result. This article looks at what meclizine actually is, whether it is a controlled substance, what the published cross reactivity literature says about antihistamines on immunoassay panels, and how a lab and a medical review officer sort out a presumptive positive before it becomes a reportable result.
What meclizine is and how it is classified
Meclizine hydrochloride is a first generation antihistamine (a piperazine derivative) used mainly to prevent and treat nausea, vomiting, and dizziness from motion sickness, and for vertigo associated with inner ear conditions. It works primarily as an H1 receptor antagonist with anticholinergic effects, which is also why it can cause drowsiness. Current official prescription and over the counter labeling for meclizine products is searchable on the National Library of Medicine's DailyMed label database, which lists the approved indications, warnings, and drug interactions for meclizine hydrochloride products.
Meclizine does not appear on the federal controlled substances schedules. The Drug Enforcement Administration maintains the current list of controlled substance schedules through its Diversion Control Division, and antihistamines like meclizine, diphenhydramine, and hydroxyzine are not scheduled drugs under the Controlled Substances Act. That classification matters for employers because it means meclizine is not a substance any standard workplace panel is designed to detect in the first place.
What a standard panel screens for, and why meclizine is not a target
Standard 5, 10, and 12 panel immunoassay screens are built around antibodies that bind to specific drug classes: amphetamines, cocaine metabolites, opiates, phencyclidine (PCP), THC metabolites, benzodiazepines, barbiturates, methadone, and a handful of others depending on the panel. Meclizine is not a target analyte on any of these panels, and it is not chemically similar to the drug classes those antibodies are built to catch. The concern raised about meclizine usually comes from confusing it with other, better documented antihistamines, most notably diphenhydramine (Benadryl), which has a longer published record of occasional immunoassay interference.
| Antihistamine | Common use | Documented immunoassay cross reactivity |
|---|---|---|
| Meclizine | Motion sickness, vertigo | No published cross reactivity identified with standard amphetamine, PCP, or opiate immunoassays |
| Diphenhydramine | Allergy, sleep aid, motion sickness | Case reports of false positive PCP and tricyclic antidepressant immunoassay results at high doses or overdose, resolved by confirmation testing |
| Hydroxyzine | Allergy, anxiety, itching | Limited published reports; not a routine amphetamine or PCP interferent at therapeutic doses |
| Cetirizine and loratadine | Non drowsy allergy relief | No meaningful published cross reactivity with standard panel classes |
What the published record actually says
For meclizine specifically, there is no published cross reactivity evidence showing it triggers a false positive on standard amphetamine, PCP, opiate, benzodiazepine, or cocaine immunoassays. That is a real and meaningful answer, not a dodge: the absence of case reports or validated interference data for meclizine on these screens means employers and employees should not expect it to cause a false positive under ordinary dosing.
Diphenhydramine is the antihistamine most often confused with meclizine in these conversations, and it does have documented interference in specific circumstances. A recent case report and literature review in a peer reviewed journal, available through the National Library of Medicine's PubMed Central archive, describes diphenhydramine overdose producing false positive tricyclic antidepressant immunoassay results, confirmed to be false by follow up testing. That literature involves diphenhydramine at high or toxic doses, not meclizine, and even then the interference was resolved through confirmation, which is exactly how the system is designed to work.
Because meclizine and diphenhydramine are frequently grouped together as "motion sickness" or "allergy" medications by people who have not read either label, it is worth being direct: no published study, FDA label warning, or NIH literature review currently documents meclizine itself as a source of immunoassay cross reactivity. If new peer reviewed evidence changes that, the correct response from a testing program is still the same process described below, not a guess about what might show up.
How GC/MS and LC/MS confirmation resolve a presumptive result
Immunoassay screens are designed to be fast and sensitive, which means they are built to flag anything that might be present rather than to prove identity. A nonnegative immunoassay result is a presumptive finding, not a final one. Laboratory confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS) identifies the exact molecule and concentration, which is how legitimate antihistamine use is distinguished from an actual controlled substance. Because meclizine is not chemically related to amphetamines, opiates, PCP, or benzodiazepines, confirmation testing would not identify it as any of those substances even in the unlikely event a screen flagged nonnegative for an unrelated reason.
The MRO review and prescription documentation step
For DOT regulated testing, every nonnegative laboratory result goes through a medical review officer before it becomes a verified result, under the procedures in 49 CFR Part 40. The MRO contacts the employee, reviews current prescriptions and over the counter medication use, and may request pharmacy records or a conversation with a prescribing provider before verifying a result as positive, negative, or refusal to test. Non-DOT programs that follow similar practices, including those referencing the Substance Abuse and Mental Health Services Administration's workplace drug testing resources, generally build in a comparable medical review step before a result is reported to an employer.
An employee taking meclizine does not need a special defense prepared in advance, because meclizine is not expected to interfere with the panels in use. If a question does come up in MRO review, having the prescription bottle, pharmacy receipt, or product packaging on hand speeds up verification. Employees should never be advised to withhold or alter specimens, and no amount of documentation substitutes for honest disclosure to the MRO.
What employers should do with a disputed result
If an employee raises meclizine or another antihistamine as an explanation for a result, the correct employer response is procedural, not medical. Route the specimen through confirmation testing if it has not already occurred, let the MRO review process run its course, and do not make employment decisions based on a screening result alone. Employers should also avoid telling employees that a medication "will never" or "can never" cause an issue; the accurate statement is that current published evidence does not show meclizine as a cross reactive interferent, and that confirmation and MRO review exist specifically to catch and resolve cases where a screening result does not match actual drug use.
Programs that want fewer disputed results in the first place generally standardize on panels and collection devices that match their population and document the chain of custody closely. American Screening Corporation supplies drug test cups and dip cards used across pre-employment, random, and reasonable suspicion programs; its drug test cup collection is one option for employers building or refreshing a program. Clinics and distributors sourcing in volume can also review options through the wholesale portal.
For related reading on antihistamines and panel screens, see Benadryl and Drug Tests: Diphenhydramine False Positives Explained and Does Hydroxyzine Show Up on a Drug Test?.
Frequently asked questions
Does meclizine show up as a positive on a drug test?
No published evidence shows meclizine causing a positive or false positive result on standard amphetamine, opiate, PCP, benzodiazepine, or cocaine immunoassay panels. It is not a target analyte on these screens and is not a controlled substance.
Is meclizine a controlled substance?
No. Meclizine does not appear on the DEA controlled substance schedules. It is available over the counter and by prescription depending on strength and formulation, as shown on its approved by FDA DailyMed labeling.
Could meclizine be confused with diphenhydramine on a drug test?
They are different molecules and the published record differs between them. Diphenhydramine has documented case reports of false positive results on certain immunoassays, mainly at high or overdose doses. Meclizine does not have comparable published cross reactivity data.
What should an employee do if meclizine is flagged during a drug test review?
Disclose current medications, including over the counter antihistamines, to the medical review officer and have the prescription or product packaging available if asked. The MRO reviews this information as part of verifying the laboratory result under 49 CFR Part 40.
Does a positive screening result mean someone used an illegal drug?
No. A nonnegative immunoassay screen is presumptive only. Laboratory confirmation by GC/MS or LC/MS and medical review officer review are required before a result is verified, and legitimate medication use is one of the explanations the MRO process is built to catch.
Can an employer skip confirmation testing if an employee mentions a medication?
Programs should follow their written policy and applicable regulations rather than make an informal exception. For DOT covered testing, confirmation and MRO review are required steps under 49 CFR Part 40 regardless of what medication an employee reports.
This article is general information, not medical or legal advice. Employers and employees should consult a medical review officer, qualified clinician, or legal counsel for guidance specific to an individual situation.